An evaluation of early medication use for COPD: a population-based cohort study

Figures & data

Table 1 Classes of first medications after diagnosis over study period

Medication	% of users (n=13,369)a
SABD	66.0
SABA alone	25.5
SAMA alone	13.4
SABA + SAMA alone	27.2
LABA (±SABD, without ICS)	2.3
LAMA (±SABD, without ICS)	2.1
ICS (any)	28.2
ICS + LABA	14.7
Others (methylxanthines, LABA + LAMA)	1.5

Note:

a Total of bolded figures =100%.

Abbreviations: SABD, short-acting bronchodilators; SABA, short-acting β-2 agonists; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-2 agonists; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroids.

Figure 1 Classes of first medications after diagnosis by year.

Abbreviations: SABD, short-acting bronchodilator; LAMA, long-acting muscarinic antagonist; LABA, long-acting β-agonist; ICS, inhaled corticosteroid.

Figure 2 Number of first medications after diagnosis for 1997 vs 2012.

Abbreviation: med, medication.

Table S1 Groupings of COPD medications used in the study analyses

Grouping by class	Medications
SABA	Fenoterol, salbutamol, terbutaline
SAMA	Ipratropium
Combinations of short-acting agents	Fenoterol/ipratropium, salbutamol/ipratropium
Methylxanthines	Aminophylline, oxtriphylline, theophylline
LABA	Formoterol, indacaterol, salmeterol
LAMA	Glycopyrronium, tiotropium
ICS	Beclomethasone, budesonide, ciclesonide, fluticasone, mometasone
ICS and LABA combinations	Formoterol/budesonide, formoterol/mometasone, salmeterol/fluticasone

Abbreviations: SABA, short-acting β-2 agonists; SAMA, short-acting muscarinic antagonist; LABA, long-acting β-2 agonists; LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroids.